Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

{gamma}-Secretase Substrate Concentration Modulates the Abeta42/Abeta40 Ratio: IMPLICATIONS FOR ALZHEIMER DISEASE.

Yin YI, Bassit B, Zhu L, Yang X, Wang C, Li YM.

J Biol Chem. 2007 Aug 10;282(32):23639-44.

2.

The molecular link between beta- and gamma-secretase activity on the amyloid beta precursor protein.

Tabaton M, Tamagno E.

Cell Mol Life Sci. 2007 Sep;64(17):2211-8. Review.

PMID:
17604999
3.

The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism.

Shen J, Kelleher RJ 3rd.

Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):403-9. Review.

4.
5.

BACE1 structure and function in health and Alzheimer's disease.

Cole SL, Vassar R.

Curr Alzheimer Res. 2008 Apr;5(2):100-20. Review.

PMID:
18393796
6.

The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.

Stockley JH, O'Neill C.

Biochem Soc Trans. 2007 Jun;35(Pt 3):574-6. Review.

PMID:
17511655
7.

Emerging Alzheimer's disease therapies: inhibition of beta-secretase.

Citron M.

Neurobiol Aging. 2002 Nov-Dec;23(6):1017-22. Review.

PMID:
12470797
8.

Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond.

Leuchtenberger S, Beher D, Weggen S.

Curr Pharm Des. 2006;12(33):4337-55. Review.

PMID:
17105431
9.

The catalytic core of gamma-secretase: presenilin revisited.

Steiner H.

Curr Alzheimer Res. 2008 Apr;5(2):147-57. Review.

PMID:
18393799
10.

The role of amyloid beta peptide 42 in Alzheimer's disease.

Findeis MA.

Pharmacol Ther. 2007 Nov;116(2):266-86. Review.

PMID:
17716740
11.

Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.

Pollack SJ, Lewis H.

Curr Opin Investig Drugs. 2005 Jan;6(1):35-47. Review.

PMID:
15675602
12.

A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis.

Sambamurti K, Suram A, Venugopal C, Prakasam A, Zhou Y, Lahiri DK, Greig NH.

Curr Alzheimer Res. 2006 Feb;3(1):81-90. Review.

PMID:
16472208
13.

Gamma-secretase: a catalyst of Alzheimer disease and signal transduction.

Li YM.

Mol Interv. 2001 Oct;1(4):198-207. Review.

PMID:
14993342
14.

Activity of gamma-secretase on substrates other than APP.

LleĆ³ A.

Curr Top Med Chem. 2008;8(1):9-16. Review.

PMID:
18220928
15.

Understanding BACE1: essential protease for amyloid-beta production in Alzheimer's disease.

Stockley JH, O'Neill C.

Cell Mol Life Sci. 2008 Oct;65(20):3265-89. doi: 10.1007/s00018-008-8271-3. Review.

PMID:
18695942
16.

The turn formation at positions 22 and 23 in the 42-mer amyloid beta peptide: the emerging role in the pathogenesis of Alzheimer's disease.

Murakami K, Masuda Y, Shirasawa T, Shimizu T, Irie K.

Geriatr Gerontol Int. 2010 Jul;10 Suppl 1:S169-79. doi: 10.1111/j.1447-0594.2010.00598.x. Review.

PMID:
20590832
17.

Secretase inhibitors and modulators for Alzheimer's disease treatment.

Tomita T.

Expert Rev Neurother. 2009 May;9(5):661-79. doi: 10.1586/ern.09.24. Review.

PMID:
19402777
18.

Alzheimer's disease sends the wrong signals--a perspective.

Neve RL.

Amyloid. 2008 Mar;15(1):1-4. doi: 10.1080/13506120701814608. Review.

PMID:
18266116
19.

Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.

Hampel H, Shen Y.

Scand J Clin Lab Invest. 2009;69(1):8-12. doi: 10.1080/00365510701864610. Review.

PMID:
18609117
20.

Therapeutic potential of gamma-secretase inhibitors and modulators.

Imbimbo BP.

Curr Top Med Chem. 2008;8(1):54-61. Review.

PMID:
18220933
Items per page

Supplemental Content

Support Center